Cabaletta Bio Shows Promising Results in Phase 1/2 Trials

Cabaletta Bio, Inc. has released the initial clinical data from the RESET-Myositis™ and RESET-SLE™ Phase 1/2 trials conducted as of June 2024. The results indicate significant progress and noteworthy changes since the last reporting period.

In the RESET-Myositis™ trial, the mean manual muscle testing (MMT) score improved from 65.7 at baseline to 70.3 at week 24. This represents a noteworthy increase of 7.0% from the last reported MMT score of 65.7. Additionally, the mean quantitative muscle testing (QMT) score showed improvement from 66.1 at baseline to 71.5 at week 24, reflecting a substantial increase of 8.2% from the previous reported QMT score of 66.1.

The RESET-SLE™ trial also demonstrated remarkable progress. The mean SLEDAI-2K score decreased from 5.6 at baseline to 3.2 at week 24, marking a significant reduction of 42.9% from the last reported SLEDAI-2K score of 5.6. Furthermore, the mean British Isles Lupus Assessment Group (BILAG) score showed improvement from 10.1 at baseline to 4.2 at week 24, indicating a substantial decrease of 58.4% from the previous reported BILAG score of 10.1.

These results underscore the positive impact of the treatments on patients participating in the trials and demonstrate promising advancements in addressing myositis and systemic lupus erythematosus (SLE). The improvements in key clinical metrics highlight the potential efficacy of the therapies and provide optimism for the future of these programs. Today the company's shares have moved -15.3% to a price of $10.64. For more information, read the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.